Loading
STAT3 (Signal transducer and activator of transcription 3) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Leukaemia, Skin cancer and 5 more. This dossier gathers the 1 product (0 approved), 1 trial, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Signal transducer and transcription activator that mediates cellular responses to interleukins, KITLG/SCF, LEP and other growth factors. Once activated, recruits coactivators, such as NCOA1 or MED1, to the promoter region of the target gene. May mediate cellular responses to activated FGFR1, FGFR2, FGFR3 and FGFR4. Upon activation of IL6ST/gp130 signalling by interleukin-6 (IL6), binds to the IL6-responsive elements identified in the promoters of various acute-phase protein genes. Activated by IL31 through IL31RA. Acts as a regulator of inflammatory response by regulating differentiation of naive CD4(+) T-cells into T-helper Th17 or regulatory T-cells (Treg): acetylation promotes its transcription activity and cell differentiation while deacetylation and oxidation of lysine residues by LOXL3 inhibits differentiation. Location: Cytoplasm; Nucleus (UniProt). Locus 17q21.2 (HGNC).
| Modality | Withdrawn or failed |
|---|---|
| Small molecule 1 |
| Trial | Setting | Result | Products | ||
|---|---|---|---|---|---|
CanStem111P NCT02993731 | 3 | Negative | Untreated metastatic pancreatic adenocarcinoma at 165 sites in 20 countries: napabucasin with nab-paclitaxel plus gemcitabine against chemotherapy alone, open-label, adaptive, with overall survival as the primary endpoint and a phospho-STAT3 biomarker subgroup | Median overall survival 11.4 months with napabucasin plus nab-paclitaxel and gemcitabine against 11.7 months with chemotherapy alone (hazard ratio 1.07, 95 percent confidence interval 0.93 to 1.23); terminated for futility. |
No recorded escape route names this target.
No pathway diagram carries this target as a node.
No companion diagnostic in the registry measures this target.
No model entry for this target yet; check the cancer entries on the models page.
No open questions recorded for this target yet. Suggest one.
Query for this target: (TITLE:"STAT3" OR ABSTRACT:"STAT3" OR TITLE:"signal transducer and activator of transcription 3" OR ABSTRACT:"signal transducer and activator of transcription 3" OR TITLE:"Signal transducer and activator of transcription 3" OR ABSTRACT:"Signal transducer and activator of transcription 3") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about STAT3, not a curated reading list.
The dossier as machine-readable JSON, at /api/v1/dossiers/stat3.json: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/stat3.json. Licence CC BY-NC 4.0.